PRODUCT MONOGRAPH

**Rapaflo®**

Silodosin

Capsules, 8 mg and 4 mg

Selective antagonist for ALPHA\textsubscript{1A} Adrenoreceptor subtype in the prostate and bladder

ATC code: G04C A04

Date of Preparation: January 14, 2015

Actavis Specialty Pharmaceuticals Co.
6733 Mississauga Road, Suite 400
Mississauga, Ontario L5N 6J5
CANADA

Control No.: 181100
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION ......................................................3
  SUMMARY OF PRODUCT INFORMATION ..........................................................3
  INDICATIONS AND CLINICAL USE ......................................................................3
  CONTRAINDICATIONS ..........................................................................................3
  WARNINGS AND PRECAUTIONS .........................................................................4
  ADVERSE REACTIONS ..........................................................................................5
  DRUG INTERACTIONS ............................................................................................9
  DOSAGE AND ADMINISTRATION ........................................................................11
  OVERDOSAGE ......................................................................................................12
  ACTION AND CLINICAL PHARMACOLOGY .......................................................12
  STORAGE AND STABILITY ..................................................................................16
  SPECIAL HANDLING INSTRUCTIONS ...............................................................17
  DOSAGE FORMS, COMPOSITION AND PACKAGING .........................................17

PART II: SCIENTIFIC INFORMATION ........................................................................18
  PHARMACEUTICAL INFORMATION .....................................................................18
  CLINICAL TRIALS ...............................................................................................18
  DETAILED PHARMACOLOGY ............................................................................24
  TOXICOLOGY ......................................................................................................26
  REFERENCES ......................................................................................................31

PART III: CONSUMER INFORMATION .....................................................................32
PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY OF PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Capsule, Immediate-Release, 8 mg and 4 mg</td>
<td>For a complete listing see Dosage Forms, Composition and Packaging section.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

RAPAFLO (silodosin) is indicated for:

- the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Geriatrics (≥ 65 years of age): RAPAFLO has been found to be safe and effective when administered at therapeutic doses (8 mg once daily) to patients over the age of 65 years (see CLINICAL TRIALS section).

Pediatrics (< 18 years of age): The safety and effectiveness of RAPAFLO in pediatric patients have not been established. RAPAFLO is not indicated for use in children (see WARNINGS AND PRECAUTIONS section).

Women: The safety and effectiveness of RAPAFLO in female patients have not been established. RAPAFLO is not indicated for use in women (see WARNINGS AND PRECAUTIONS section).

CONTRAINDICATIONS

- RAPAFLO (silodosin) is contraindicated in patients known to have hypersensitivity to silodosin or any component of the RAPAFLO formulation. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.
- RAPAFLO should not be administered to patients with severe hepatic impairment (Child-Pugh scores ≥ 10) (see WARNINGS AND PRECAUTIONS section).
- RAPAFLO should not be administered to patients with severe renal impairment (CCr < 30 mL/min) (see WARNINGS AND PRECAUTIONS section).
RAPAFLO should not be administered to patients using concomitant potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) (see WARNINGS AND PRECAUTIONS section).

RAPAFLO should not be administered to patients using concomitant alpha-blockers (e.g., prazosin, terazosin, doxazosin) (see WARNINGS AND PRECAUTIONS section).

WARNINGS AND PRECAUTIONS

As with all α1-adrenoceptor antagonists, a reduction in blood pressure can occur in individual cases during treatment with RAPAFLO, as a result of which, rarely, syncope can occur. At the first signs of orthostatic hypotension (dizziness, weakness), the patient should sit or lie down until the symptoms have disappeared (see WARNINGS AND PRECAUTIONS, Cardiovascular section and ADVERSE REACTIONS section).

Patients beginning treatment with RAPAFLO should be cautioned to avoid situations where injury could result should syncope occur.

General

Prostatic carcinoma: Carcinoma of the prostate and BPH cause many of the same symptoms. These two diseases frequently co-exist. Therefore, patients thought to have BPH should be examined prior to starting therapy with RAPAFLO to rule out the presence of carcinoma of the prostate.

Carcinogenesis and Mutagenesis

Carcinogenicity and mutagenicity studies have been performed in animals (see TOXICOLOGY section).

Cardiovascular

RAPAFLO is not indicated for the treatment of hypertension.

Orthostatic hypotension, with or without symptoms (e.g., dizziness) may develop when beginning RAPAFLO treatment. As with other alpha-blockers, there is potential for syncope. Patients should be cautioned about driving, operating machinery, or performing hazardous tasks when initiating therapy.

RAPAFLO should not be administered to patients using concomitant alpha-blockers. RAPAFLO should be administered with caution to patients using other concomitant pharmaceuticals known or suspected of inducing orthostatic hypotension or syncope (see ADVERSE REACTIONS, Vascular Disorders section and DRUG INTERACTIONS, Drug-Drug Interactions section).

Endocrine and Metabolism

RAPAFLO should not be administered to patients using concomitant potent CYP3A4 inhibitors.
**Hepatic**

RAPAFLO should not be administered to patients with severe hepatic insufficiency (Child-Pugh scores $\geq 10$).

**Ophthalmologic**

**Intraoperative Floppy Iris Syndrome** has been observed during cataract surgery in some patients on alpha-1 blockers or previously treated with alpha-1 blockers. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents; progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs; and potential prolapse of the iris toward the phacoemulsification incisions. Patients planning cataract surgery should be told to inform their ophthalmologist that they are taking RAPAFLO.

**Renal**

RAPAFLO should not be administered to patients with severe renal insufficiency (CCr < 30 mL/min). In patients with moderate renal impairment (CCr 30-50 mL/min), the dose should be reduced to 4 mg once daily taken with a meal. No dosage adjustment is needed in patients with mild renal impairment (CCr 50-80 mL/min).

**Special Populations**

**Pregnant Women:** RAPAFLO is not indicated nor recommended for use in women. No embryotoxic and/or teratogenic effects in rats or rabbits were observed with RAPAFLO.

**Nursing Women:** RAPAFLO is not indicated nor recommended for use in women. It is unknown if the drug is excreted in human milk.

**Pediatrics (< 18 years of age):** RAPAFLO is not indicated for use in children.

**Geriatrics (≥ 65 years of age):** In double-blind, placebo-controlled, 12-week clinical studies of RAPAFLO, 259 (55.6%) patients were under 65 years of age, 207 (44.4%) patients were 65 years of age and over, while 60 (12.9%) patients were 75 years of age and over. Orthostatic hypotension was reported in 2.3% of RAPAFLO patients < 65 years of age (1.2% for placebo), 2.9% of RAPAFLO patients $\geq$ 65 years of age (1.9% for placebo), and 5.0% of patients $\geq$ 75 years of age (0% for placebo). There were otherwise no significant differences in safety or effectiveness between older and younger patients.

**ADVERSE REACTIONS**

**Adverse Drug Reaction Overview**

Retrograde ejaculation and dizziness are the most frequent adverse events with RAPAFLO. Retrograde ejaculation is reversible upon discontinuation of the drug.
Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

In U.S. Phase 3 clinical trials, 897 patients with BPH were exposed to 8 mg RAPAFLO daily. This includes 486 patients exposed for 6 months and 168 patients exposed for 1 year. The population was 44 to 87 years of age, and predominantly Caucasian. Of these patients, 42.8% were 65 years of age or older and 10.7% were 75 years of age or older.

Safety information was derived from two U.S. Phase 3 double-blind, placebo-controlled clinical studies (Studies 1 and 2) in which 466 patients were administered RAPAFLO and 457 patients were administered placebo. At least one treatment-emergent adverse reaction was reported by 55.2% of RAPAFLO treated patients (36.8% for placebo treated). A total of 6.4% of RAPAFLO treated patients (2.2% for placebo treated) discontinued therapy due to an adverse reaction (treatment-emergent), the most common reaction being retrograde ejaculation (2.8%) for RAPAFLO treated patients. Retrograde ejaculation is reversible upon discontinuation of treatment.

The incidence of adverse treatment-emergent events listed in the following table were derived from two 12-week, multicenter, double-blind, placebo-controlled clinical studies of RAPAFLO 8 mg daily in BPH patients. Adverse events that occurred in at least 2% of patients treated with RAPAFLO and more frequently than with placebo are shown in Table 1.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Adverse Treatment-Emergent Events Occurring in ≥ 2% of Patients in 12-week, Placebo-Controlled Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adverse Events</strong></td>
<td><strong>RAPAFLO</strong></td>
</tr>
<tr>
<td></td>
<td><strong>(N = 466)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>n (%)</strong></td>
</tr>
<tr>
<td>Retrograde Ejaculation</td>
<td>131 (28.1)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>15 (3.2)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>12 (2.6)</td>
</tr>
<tr>
<td>Orthostatic Hypotension</td>
<td>12 (2.6)</td>
</tr>
<tr>
<td>Headache</td>
<td>11 (2.4)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>11 (2.4)</td>
</tr>
<tr>
<td>Nasal Congestion</td>
<td>10 (2.1)</td>
</tr>
</tbody>
</table>
In Studies 1 and 2, treatment-related adverse events that were reported as ≥ 1% and < 2% of patients receiving RAPAFLO and occurred more frequently than with placebo are presented in Table 2.

**Table 2** Treatment-Related Adverse Events Occurring in ≥ 1% and < 2% of Patients in 12-week, Placebo-Controlled Clinical Trials

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>RAPAFLO (N = 466) % of patients</th>
<th>Placebo (N = 457) % of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>6 (1.3)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orthostatic Hypotension</td>
<td>9 (1.9)</td>
<td>7 (1.5)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (1.1)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Respiratory Thoracic and Mediastinal Disorders</td>
<td>7 (1.5)</td>
<td>1 (0.2)</td>
</tr>
</tbody>
</table>

**Vascular Disorders**

In two U.S. Phase 3 double-blind, placebo-controlled clinical studies (Studies 1 and 2), treatment-related dizziness was seen in 2.4% of patients receiving silodosin and 0.7% of those receiving placebo.

A test for orthostatic hypotension was conducted 2 to 6 hours after the first dose in the two 12-week, double-blind, placebo-controlled clinical studies. After the patient had been at rest in a supine position for 5 minutes, the patient was asked to stand. Blood pressure and heart rate were assessed at 1 minute and 3 minutes after standing. A positive result was defined as a > 30 mmHg decrease in systolic blood pressure, or a > 20 mmHg decrease in diastolic blood pressure, or a > 20 bpm increase in heart rate, as presented in Table 3.

**Table 3** Summary of Orthostatic Test Results in 12-week, Placebo-Controlled Clinical Trials

<table>
<thead>
<tr>
<th>Time of Measurement</th>
<th>Test Result</th>
<th>RAPAFLO (N = 466) % of patients</th>
<th>Placebo (N = 457) % of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Minute After Standing</td>
<td>Negative</td>
<td>459 (98.7%)</td>
<td>454 (99.6%)</td>
</tr>
<tr>
<td></td>
<td>Positive</td>
<td>6 (1.3%)</td>
<td>2 (0.4%)</td>
</tr>
<tr>
<td>3 Minutes After Standing</td>
<td>Negative</td>
<td>456 (98.1%)</td>
<td>454 (99.6%)</td>
</tr>
<tr>
<td></td>
<td>Positive</td>
<td>9 (1.9%)</td>
<td>2 (0.4%)</td>
</tr>
</tbody>
</table>
Less Common Clinical Trial Adverse Drug Reactions (< 1%)

Vascular Disorders

One case of syncope in a patient taking prazosin concomitantly was reported in the RAPAFLO treatment group. In a 9-month open-label safety study, loss of consciousness was observed in one patient. Because the investigator who examined this patient could not rule out the possibility that silodosin was causative, this event was considered related to silodosin use.

Post-Market Adverse Drug Reactions

The following adverse events have been identified during post-approval use of silodosin. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

Eye Disorders:
Cases of Intraoperative Floppy Iris Syndrome have been reported (see WARNINGS AND PRECAUTIONS, Ophthalmologic).

Hepatobiliary Disorders:
Cases of jaundice, impaired hepatic function associated with increased transaminase values, and abnormal liver function tests have been reported.

Immune System Disorders:
Cases of allergic-type reactions, not limited to skin reactions including swollen tongue and pharyngeal edema resulting in hospitalization have been reported.

Skin and Subcutaneous Tissue Disorders:
Cases of toxic skin eruption (drug eruption), purpura, skin rash, pruritus, urticaria, angioedema, dermatitis exfoliative, swelling face, erythema and erythema multiforme have been reported.

Cardiac Disorders:
Cases of tachycardia and palpitations have been reported.

Respiratory Disorders:
Cases of dyspnoea, interstitial lung disease, eosinophilic pneumonia, and eosinophilic pneumonia (acute) have been reported.
DRUG INTERACTIONS

Overview

RAPAFLO is not an inducer or an inhibitor of any of the principal hepatic enzymes involved in the metabolism of other drugs.

CYP3A4 is a principal hepatic enzyme isoform involved in the metabolism of RAPAFLO.

**Potent CYP3A4 inhibitors**, such as ketoconazole, itraconazole, clarithromycin and ritonavir, increase RAPAFLO blood levels and exposure (Area Under the Curve - AUC). RAPAFLO should not be co-administered with potent inhibitors of CYP3A4 (see CONTRAINDICATIONS). See Drug-Drug Interactions for details of increased RAPAFLO blood levels. As this is only a partial list, the physician is advised to consult current scientific literature regarding other CYP3A4 competitive inhibitors prior to prescribing RAPAFLO if other concomitant medications are used.

Moderate CYP3A4 inhibitor diltiazem increased the RAPAFLO AUC by approximately 30%, but the maximum concentration (Cmax) and half-life were not affected. No dose adjustment is required.

It is not known how combined exposure of any medications metabolized by the CYP3A4 hepatic enzyme isoform (such as alpha₁-blockers), herbal remedies (particularly St. John’s Wort, Milk Thistle), and grapefruit juice may influence the overall efficacy and unwanted side effects of these medications. Therefore, caution should be exercised.

**Strong P-glycoprotein (P-gp) Inhibitors**

*In vitro* studies indicated that silodosin is a P-gp substrate. Ketoconazole, a CYP3A4 inhibitor that also inhibits P-gp, caused significant increase in exposure to silodosin. Inhibition of P-gp may lead to increased silodosin concentration. RAPAFLO is therefore not recommended in patients taking strong P-gp inhibitors such as cyclosporine.

Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

**Table 4 Established or Potential Drug-Drug Interactions**

<table>
<thead>
<tr>
<th>Drug / Class</th>
<th>Reference</th>
<th>Effect</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketoconazole, 400 mg</td>
<td>CT</td>
<td>Increased silodosin plasma concentration 3.7-fold</td>
<td>Recommend not using silodosin with potent CYP3A4 inhibitors.</td>
</tr>
<tr>
<td>Potent CYP3A4 Inhibitors (ritonavir)</td>
<td>T</td>
<td>Increased silodosin plasma concentration</td>
<td>Recommend not using silodosin with potent CYP3A4 inhibitors.</td>
</tr>
<tr>
<td>Strong P-glycoprotein (P-gp) Inhibitors</td>
<td>T</td>
<td>Increased silodosin plasma concentration</td>
<td>Recommend not using silodosin with potent P-gp inhibitors.</td>
</tr>
<tr>
<td>(cyclosporine)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 4  Established or Potential Drug-Drug Interactions

<table>
<thead>
<tr>
<th>Drug / Class</th>
<th>Reference</th>
<th>Effect</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diltiazem, 300 mg</td>
<td>CT</td>
<td>Increased silodosin plasma AUC by 30%</td>
<td>AUC was elevated by approximately 30%, but other parameters were not increased. No dosage adjustment needed.</td>
</tr>
<tr>
<td>Digoxin, 0.25 mg</td>
<td>CT</td>
<td>None</td>
<td>Seven day co-administration did not influence the steady state pharmacokinetics of either drug.</td>
</tr>
<tr>
<td>Sildenafil, 100 mg</td>
<td>CT</td>
<td>In subjects &lt; 65 years of age a mean increase in heart rate was observed during orthostatic tests, while those ≥ 65 demonstrated a slight mean decrease in blood pressure.</td>
<td>No events of symptomatic orthostasis occurred in subjects receiving silodosin with sildenafil, nor were there any events of dizziness.</td>
</tr>
<tr>
<td>Tadalafil, 20 mg</td>
<td>CT</td>
<td>In subjects &lt; 65 years of age a mean increase in heart rate was observed during orthostatic tests, while those ≥ 65 demonstrated a slight mean decrease in blood pressure.</td>
<td>No events of symptomatic orthostasis occurred in subjects receiving silodosin with tadalafil, nor were there any events of dizziness.</td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>CT</td>
<td>Slightly higher incidence of adverse effects when used concomitantly</td>
<td>Approximately one-third of the patients in the two Phase 3 clinical studies used concomitant antihypertensive medications. The incidence of dizziness and orthostatic hypotension in these patients was higher than in the general silodosin population (4.6% versus 3.8% and 3.4% versus 3.2%, respectively). Exercise caution during concomitant use with antihypertensives and monitor patients for possible adverse events.</td>
</tr>
<tr>
<td>Alpha-1 blockers</td>
<td>T</td>
<td>Increase in orthostatic effects</td>
<td>The pharmacodynamic interactions may be expected, and silodosin should not be used in combination with other alpha-blockers. Nevertheless, exercise caution during concomitant use with antihypertensives and monitor patients for possible adverse events.</td>
</tr>
</tbody>
</table>

Legend: CT = Clinical Trial; T = Theoretical

**Drug-Food Interactions**

The oral bioavailability of silodosin is not changed when taken with food. Food decreases $C_{\text{max}}$ by approximately 30% and increases $t_{\text{max}}$ by approximately 1 hour.

RAPAFLO should be taken orally once daily with a meal.
**Drug-Herb Interactions**

Interactions with herbal products have not been established.

**Drug-Laboratory Test Interactions**

No laboratory test interactions were observed during clinical evaluations. Treatment with RAPAFLO for up to 52 weeks had no significant effect on prostate-specific antigen (PSA).

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**

Before prescribing RAPAFLO, consider the following situations that may affect dosing of the drug:

- Potent CYP3A4 inhibitors (see WARNINGS AND PRECAUTIONS, Endocrine and Metabolism section)
- Hepatic insufficiency (see WARNINGS AND PRECAUTIONS, Hepatic section)
- Renal insufficiency (see WARNINGS AND PRECAUTIONS, Renal section)

**Recommended Dose and Dosage Adjustment**

RAPAFLO (silodosin) 8 mg once daily with a meal is recommended as the dose for the treatment of the signs and symptoms of BPH.

Renal impairment: RAPAFLO is contraindicated in patients with severe renal impairment (CCr < 30 mL/min). In patients with moderate renal impairment (CCr 30-50 mL/min), the dose should be reduced to 4 mg once daily taken with a meal. No dosage adjustment is needed in patients with mild renal impairment (CCr 50-80 mL/min).

Hepatic impairment: RAPAFLO has not been studied in patients with severe hepatic impairment (Child-Pugh score $\geq 10$) and is therefore contraindicated in these patients. No dosage adjustment is needed in patients with mild or moderate hepatic impairment.

**Missed Dose**

If a dose of RAPAFLO is missed, the missed dose can be taken later the same day. If a day is missed, the missed dose should be skipped and the regular dosing schedule should be resumed.

Doses must not be doubled.

**Administration**

RAPAFLO should be taken orally once daily with a meal.

RAPAFLO capsules may also be administered by carefully opening the capsule and sprinkling the powder inside on a spoonful of applesauce. The applesauce should be swallowed immediately without chewing and followed with a glass of cool water to ensure complete
swallowing of the powder. The applesauce used should not be hot, and it should be soft enough to be swallowed without chewing. Any powder/applesauce mixture should be used immediately and not stored for future use. Subdividing the contents of a RAPAFLO capsule is not recommended.

**OVERDOSAGE**

RAPAFLO was evaluated at doses of up to 48 mg/day in healthy male subjects. The dose-limiting adverse event was orthostatic hypotension.

Should overdose of RAPAFLO lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by maintaining the patient in the supine position. If this measure is inadequate, administration of intravenous fluid should be considered. If necessary, vasopressors could be used, and renal function should be monitored and supported as needed. Dialysis is unlikely to be of significant benefit since silodosin is highly (97%) protein bound.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**

Silodosin, indicated for the treatment of benign prostatic hyperplasia (BPH), is a uroselective antagonist of post-synaptic \( \alpha_{1A} \)-adrenoceptors located in the prostate, prostatic capsule, bladder base, bladder neck, and prostatic urethra.

**Pharmacodynamics**

The clinical manifestations of benign prostatic hyperplasia (BPH) are due to bladder outlet obstruction caused by anatomical (static) and functional (dynamic) factors. The static component is related to an increase in prostate size which may not cause symptoms. The dynamic component is related primarily to an increase in smooth muscle tone in the prostate, prostatic capsule, bladder base, bladder neck, and prostatic urethra. This increased tone is mediated by the activation of \( \alpha_1 \)-adrenoceptors and leads to an increased resistance to urinary voiding and the symptoms of BPH such as a hesitant, interrupted, weak stream; urgency and leaking or dribbling; and/or more frequent urination, especially at night.

The treatment effects of silodosin are related to its effects on sympathetic nervous system adrenoreceptors. These adrenoreceptors are G protein coupled transmembrane receptors that mediate catecholaminergic actions. To date, three distinct members of this family have been identified: \( \alpha_{1A}, \alpha_{1B}, \) and \( \alpha_{1D} \). \( \alpha_{1A} \)-adrenoreceptors are expressed abundantly in the prostatic stroma, while \( \alpha_{1D} \)-adrenoreceptors are the predominate subtype in the nasal passages, spinal cord, and human bladder. \( \alpha_{1A} \)-adrenoreceptors and \( \alpha_{1B} \)-adrenoreceptors are both expressed within human vascular smooth muscle. However, as patients age, the ratio between these
subtypes changes with $\alpha_{1B}$-adrenoreceptors becoming predominate in the vasculature, particularly in patients over 65 years of age.

Silodosin is highly selective for $\alpha_{1A}$-adrenoreceptors. Blockade of these $\alpha_{1A}$-adrenoreceptors causes smooth muscle in the prostate to relax, resulting in an improvement in urine flow and a reduction in BPH symptoms. Silodosin has a substantially lower affinity for the $\alpha_{1B}$-adrenoreceptors.

An *in vitro* study examining binding affinity of silodosin to the three subtypes of the alpha-1 adrenoreceptors (alpha-1A, alpha-1B, and alpha-1D) was conducted. The results of the study demonstrated that silodosin binds with high affinity to the alpha-1A subtype and that the $\alpha_{1A}/\alpha_{1B}$ binding ratio of silodosin is extremely high (162:1), while the $\alpha_{1A}/\alpha_{1D}$ binding ratio of silodosin is moderate (55:1). This is illustrated in the table below.

**Table 5** Affinity for Human $\alpha_{1A}$-AR subtype and $\alpha_{1A}$-AR Subtype Selectivity of Silodosin

<table>
<thead>
<tr>
<th>Test Drug</th>
<th>$\alpha_{1A}$-AR</th>
<th>$\alpha_{1B}$-AR</th>
<th>$\alpha_{1D}$-AR</th>
<th>$\alpha_{1A}/\alpha_{1B}$ Ratio</th>
<th>$\alpha_{1A}/\alpha_{1D}$ Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>silodosin (KMD-3213)</td>
<td>10.4 ± 0.07</td>
<td>8.19 ± 0.04</td>
<td>8.66 ± 0.02</td>
<td>162</td>
<td>55.0</td>
</tr>
</tbody>
</table>

The pKi value in the table represents the mean ± S.E. of 3 runs.

a) The subtype selectivity ($\alpha_{1A}/\alpha_{1B}$ and $\alpha_{1A}/\alpha_{1D}$ ratios) was calculated from the ratio after converting the concentration, specifically, using $10^M [M=pKi(\alpha_{1A}) - pKi(\alpha_{1B} \text{ or } \alpha_{1D})]$. (Example: M=10.4-8.18 = 2.21 $10^{2.21} = 162$)

In placebo-controlled clinical studies in patients with BPH, RAPAFLO was shown to significantly increase average urine peak flow rate (Qmax) by 30% which is observed after the first dose. These favorable urodynamic effects may have been responsible for the improvement of lower tract irritative and obstructive symptoms that were observed. The Quality of Life Index also significantly improved in the RAPAFLO patients.

**Electrocardiography**

The effect of RAPAFLO on QT interval was evaluated in a double-blind, randomized, active- (moxifloxacin) and placebo-controlled, parallel-group study in 183 healthy male subjects aged 18 to 45 years. Subjects received RAPAFLO 8 mg, RAPAFLO 24 mg, or placebo once daily for 5 days, or a single dose of moxifloxacin 400 mg on Day 5 only. The 24 mg dose of RAPAFLO was selected to achieve blood levels of silodosin that may be seen in a “worst-case” scenario exposure (i.e., in the setting of concomitant renal disease or use of strong CYP3A4 inhibitors). QT interval was measured during a 24-hour period following dosing on Day 5 (at silodosin steady state).

In 183 patients analyzed, RAPAFLO was not associated with an increase in individual corrected (QTcI) QT interval at any time during steady state measurement, while moxifloxacin, the active control, was associated with a maximum 9.59 msec increase in QTcI.

There has been no signal of Torsade de Pointes in the post-marketing experience of silodosin.
Pharmacokinetics

The pharmacokinetics of silodosin have been evaluated in adult male subjects with doses ranging from 0.1 mg to 24 mg per day. The pharmacokinetics of silodosin are linear throughout this dosage range.

Absorption:
The pharmacokinetic characteristics of silodosin 8 mg once daily were determined in a multi-dose, open-label, 7-day pharmacokinetic study completed in 19 healthy, target-aged (≥ 45 years of age) male subjects. Table 6 and Figure 1 present the steady state pharmacokinetics of this study.

**Table 6**  Mean (±SD) Steady State Pharmacokinetic Parameters in Males Following Silodosin 8 mg Once Daily with a Meal

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>61.6 ± 27.54</td>
</tr>
<tr>
<td>t&lt;sub&gt;max&lt;/sub&gt; (hours)</td>
<td>2.6 ± 0.90</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt; (hours)</td>
<td>13.3 ± 8.07</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;ss&lt;/sub&gt; (ng•hr/mL)</td>
<td>373.4 ± 164.94</td>
</tr>
</tbody>
</table>

C<sub>max</sub> = maximum concentration, t<sub>max</sub> = time to reach C<sub>max</sub>, t<sub>1/2</sub> = elimination half-life, AUC<sub>ss</sub> = steady state area under the concentration-time curve

**Figure 1**  Mean (±SD) Silodosin Steady State Plasma Concentration-Time Profile in Healthy Target-Aged Subjects following Silodosin 8 mg Once Daily with Food

The absolute bioavailability is approximately 32%.
The effect of a moderate fat, moderate calorie meal was variable and decreased silodosin C_max by approximately 18 - 43% and AUC by 4 - 49% across three different studies.

**Distribution:**

Silodosin has an apparent volume of distribution of 49.5 L and is approximately 97% protein bound.

**Metabolism:**

Silodosin undergoes extensive metabolism through glucuronidation, alcohol and aldehyde dehydrogenase, and cytochrome P450 3A4 (CYP3A4) pathways. The main metabolite of silodosin is a glucuronide conjugate (KMD-3213G) that is formed via direct conjugation of silodosin by UDP-glucuronosyltransferase 2B7 (UGT2B7). Co-administration with inhibitors of UGT2B7 (e.g., probenecid, valproic acid, fluconazole) may potentially increase exposure to silodosin. KMD-3213G, which has been shown in vitro to be active, has an extended half-life (approximately 24 hours) and reaches plasma exposure (AUC) approximately 4 times greater than that of silodosin. The second major metabolite (KMD-3293) is formed via alcohol and aldehyde dehydrogenases and reaches plasma exposures similar to that of silodosin. KMD-3293 is not expected to contribute significantly to the overall pharmacologic activity of RAPAFLO.

**Excretion:**

Following oral administration of 14C-labeled silodosin, the recovery of radioactivity after 10 days was approximately 33.5% in urine and 54.9% in feces. After intravenous administration, the plasma clearance of silodosin was approximately 10 L/hour.

**Special Populations and Conditions**

**Pediatric:**

RAPAFLO has not been evaluated in patients less than 18 years of age.

**Geriatric:**

A study comparing 16 males 65 to 75 years of age, 15 males > 75 years of age, and 16 males 45 to 64 years of age was conducted. The exposure (AUC) and elimination half-life of silodosin were approximately 10% less and 17% greater, respectively, in geriatric males 65 to 75 years of age than the younger subjects, and approximately 16% less and 35% greater, respectively in geriatric males > 75 years of age than the younger subjects. A decrease in C_max of 13% and 40% was seen in males 65 to 75 years of age and > 75 years of age, respectively. Because of the modest degree of these changes, no dose adjustment is needed in elderly subjects (see WARNINGS AND PRECAUTIONS, Geriatrics section).

**Gender:**

RAPAFLO has not been evaluated in women.
Race:

No clinical studies specifically investigating the effects of race have been performed. However, available clinical data do not suggest clinically important differences.

Hepatic Insufficiency:

In a study comparing nine male patients with moderate hepatic impairment (Child-Pugh scores 7 to 9), to nine healthy male subjects, the single dose pharmacokinetic disposition of silodosin was not significantly altered in the patients with moderate hepatic impairment. No dosing adjustment is required in patients with mild or moderate hepatic impairment. The pharmacokinetics of silodosin in patients with severe hepatic impairment have not been studied. RAPAFLO should not be administered to patients with severe hepatic impairment (Child-Pugh scores ≥ 10).

Renal Insufficiency:

In a study with six subjects with moderate renal impairment, the total silodosin (bound and unbound) AUC, $C_{\text{max}}$, and elimination half-life were 3.2-, 3.1-, and 2-fold higher, respectively, compared to seven subjects with normal renal function. The unbound silodosin AUC and $C_{\text{max}}$ were 2.0- and 1.5-fold higher, respectively, in subjects with moderate renal impairment compared to the normal controls.

In another study with eight subjects with mild and moderate renal impairment, and five subjects with severe renal impairment, the total silodosin AUC, $C_{\text{max}}$, and elimination half-life were 1.9-, 1.7-, and 1.3-fold higher for the mild, and 2.2-, 1.5-, and 1.7-fold higher for moderate compared to eight subjects with normal renal function. The increase in exposure to unbound silodosin was greater in patients with severe renal impairment ($C_{\text{max}}$ and AUC 2.2- and 3.7-fold, respectively, compared to subjects with normal renal function) than in patients with moderate and mild impairment ($C_{\text{max}}$ and AUC 1.6- and 1.8-fold, respectively).

In controlled and uncontrolled clinical studies, the incidence of orthostatic hypotension and dizziness was greater in subjects with moderate renal impairment treated with 8 mg RAPAFLO daily than in subjects with normal or mildly impaired renal function.

RAPAFLO is contraindicated in patients with severe renal impairment (CCr < 30 mL/min). In patients with moderate renal impairment (CCr 30-50 mL/min), the dose should be reduced to 4 mg once daily taken with a meal. No dosage adjustment is needed in patients with mild renal impairment (CCr 50-80 mL/min).

STORAGE AND STABILITY

Store at controlled room temperature (15°C to 30°C). Keep out of reach of children. Protect from light and moisture.
SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Each RAPAFLO 8 mg capsule for oral administration contains 8 mg silodosin, and the following inactive ingredients: D-mannitol, magnesium stearate, pregelatinized starch, and sodium lauryl sulfate. The size #1 hard gelatin capsules contain gelatin and titanium dioxide. The capsules are printed with edible ink containing FD&C Blue No. 1 Aluminum Lake and yellow iron oxide. Cap is imprinted with “WATSON 152” in green. Body is imprinted with “8 mg” in green. 8 mg capsules are supplied in unit of use HDPE bottles of:

- 30 capsules
- 90 capsules

Not all pack sizes may be available on the Canadian market.

Each RAPAFLO 4 mg capsule for oral administration contains 4 mg silodosin, and the following inactive ingredients: D-mannitol, magnesium stearate, pregelatinized starch, and sodium lauryl sulfate. The size #3 hard gelatin capsules contain gelatin and titanium dioxide. The capsules are printed with edible ink containing yellow iron oxide. Cap is imprinted with “WATSON 151” in gold. Body is imprinted with “4 mg” in gold. 4 mg capsules are supplied in unit of use HDPE bottles of:

- 30 capsules
- 90 capsules

Not all pack sizes may be available on the Canadian market.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

**Common Name:** silodosin

**Chemical name:** \((-1)-(3\text{-}\text{Hydroxypropyl})\text{-}5\text{-}[(2R)\text{-}2\text{-}(\text{2}\text{-}(\text{2,2,2}\text{-}\text{trifluoroethoxy})\text{-}\text{phenoxy})\text{ethyl}]\text{amino})\text{propyl}]\text{-}2,3\text{-}\text{dihydro}-1H\text{-}\text{indole}-7\text{-}\text{carboxamide.}

**Molecular formula and molecular mass:** $C_{25}H_{32}F_3N_3O_4$; 495.53

**Structural formula:**

![Structural formula of silodosin]

**Physiochemical properties:** Silodosin is a white to pale yellowish white powder that melts at approximately 105 to 109°C. It is very soluble in acetic acid, freely soluble in alcohol, and very slightly soluble in water.

CLINICAL TRIALS

**Study Demographic and Trial Design**

**Benign Prostatic Hyperplasia (BPH):**

Two 12-week, randomized, double-blind, placebo-controlled, multicenter studies were conducted with 8 mg daily of silodosin. In these two studies, 923 patients [mean age 64.6 years; Caucasian (89.3%), Hispanic (4.9%), Black (3.9%), Asian (1.2%), Other (0.8%)] were randomized and 466 patients received RAPAFLO (silodosin) 8 mg daily. The two studies were identical in design except for the inclusion of pharmacokinetic sampling in Study 1. The primary efficacy assessment was the International Prostate Symptom Score (IPSS) which evaluated irritative (frequency, urgency, and nocturia), and obstructive (hesitancy, incomplete emptying,
intermittency, and weak stream) symptoms. Maximum urine flow rate (Qmax) was a secondary efficacy measure.

**Study Results**

Mean changes from baseline to last assessment (Week 12) in total IPSS score were statistically significantly greater for groups treated with RAPAFLO than those treated with placebo in both studies (Table 7 and Figure 2 and Figure 3).

### Table 7  
**Mean Change from Baseline in International Prostate Symptom Score (IPSS) in Two Randomized, Controlled, Double-Blind Studies**

<table>
<thead>
<tr>
<th>Total Symptom Score</th>
<th>Study 1</th>
<th>Study 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RAPAFLO 8 mg (n = 233)</td>
<td>Placebo (n = 228)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 to 4 Day Change</td>
<td>-3.9 (5.40)</td>
<td>-2.0 (4.34)</td>
</tr>
<tr>
<td>From Baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 12 / LOCF</td>
<td>-6.5 (6.73)</td>
<td>-3.6 (5.85)</td>
</tr>
<tr>
<td>Change from Baseline</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LOCF – Last observation carried forward for those not providing data at 12 weeks of treatment.

**Figure 2  
Mean Change from Baseline in IPSS Total Score by Treatment Group and Visit in Study 1**

B – Baseline determination taken Day 1 of the study before the initial dose. Subsequent values are observed cases except for LOCF values.

LOCF – Last observation carried forward for those not completing 12 weeks of treatment.
RAPAFLO® Product Monograph

Figure 3  Mean Change from Baseline in IPSS Total Score by Treatment Group and Visit in Study 2

![Graph showing mean change from baseline in IPSS total score by treatment group and visit in Study 2.]

B – Baseline determination taken Day 1 of the study before the initial dose. Subsequent values are observed cases except for LOCF values.

LOCF – Last observation carried forward for those not providing data at 12 weeks of treatment.

RAPAFLO produced highly significant reductions (p < 0.0001) of total IPSS scores at all time points in the studies, demonstrating both rapid (within 3 to 4 days) and sustained positive effects.

RAPAFLO produced significant, rapid, and sustained reductions in both irritative and obstructive symptoms as measured by the change from baseline in the appropriate IPSS subscales. Table 8 and Table 9 present IPSS irritative and obstructive subscale results.

Table 8  Mean Change (SD) from Baseline in the IPSS Irritative Symptoms Subscale in Two Randomized, Controlled, Double-Blind Studies

<table>
<thead>
<tr>
<th>Irritative Symptom Score</th>
<th>Study 1</th>
<th></th>
<th>Study 2</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RAPAFLO 8 mg (n = 233)</td>
<td>Placebo (n = 228)</td>
<td>p-value</td>
<td>RAPAFLO 8 mg (n = 233)</td>
<td>Placebo (n = 229)</td>
</tr>
<tr>
<td>Baseline</td>
<td>9.5 (2.56)</td>
<td>9.4 (2.44)</td>
<td></td>
<td>9.2 (2.62)</td>
<td>9.2 (2.59)</td>
</tr>
<tr>
<td>3 to 4 Day Change from Baseline</td>
<td>-1.3 (2.42)</td>
<td>-0.8 (2.17)</td>
<td>0.0192</td>
<td>-1.5 (2.29)</td>
<td>-0.9 (2.15)</td>
</tr>
<tr>
<td>Week 12 / LOCF Change from Baseline</td>
<td>-2.3 (2.97)</td>
<td>-1.4 (2.70)</td>
<td>0.0004</td>
<td>-2.4 (2.89)</td>
<td>-1.3 (2.62)</td>
</tr>
</tbody>
</table>

LOCF – Last observation carried forward for those not providing data at 12 weeks of treatment.
### Table 9  Mean Change (SD) from Baseline in the IPSS Obstructive Symptoms Subscale in Two Randomized, Controlled, Double-Blind Studies

| Obstructive Symptom Score | Study 1 | | Study 2 | |  
|---------------------------|---------|---|---------|---|---|---|
|                           | RAPAFLO 8 mg (n = 233) | Placebo (n = 228) | p-value | RAPAFLO 8 mg (n = 233) | Placebo (n = 229) | p-value |  
| Baseline                  | 12.0 (3.85) | 12.0 (3.57) |   | 12.0 (3.26) | 11.9 (3.49) |   |  
| 3 to 4 Day Change from Baseline | -2.6 (3.57) | -1.2 (2.91) | < 0.0001 | -2.9 (3.53) | -1.6 (3.06) | < 0.0001 |  
| Week 12 / LOCF Change from Baseline | -4.2 (4.32) | -2.2 (3.75) | < 0.0001 | -3.9 (4.31) | -2.1 (3.77) | < 0.0001 |  

LOCF – Last observation carried forward for those not providing data at 12 weeks of treatment.

RAPAFLO produced rapid and significant increases in maximum urinary flow rates from baseline to last assessment versus placebo in both studies (Table 10 and Figure 4 and Figure 5). Statistically significant treatment effects on maximum urine flow rates were noted within 2 to 6 hours after the first dose and at the end of both Study 1 and 2.

Table 10  Mean Change (SD) from Baseline in Maximum Urinary Flow Rate (mL/sec) in Two Randomized, Controlled, Double-Blind Studies

| Mean Maximum Flow Rate (mL/sec) | Study 1 | | Study 2 | |  
|-------------------------------|---------|---|---------|---|---|---|
|                              | RAPAFLO 8 mg (n = 233) | Placebo (n = 228) | p-value | RAPAFLO 8 mg (n = 233) | Placebo (n = 229) | p-value |  
| Baseline                     | 9.0 (2.60) | 9.0 (2.85) |   | 8.4 (2.48) | 8.7 (2.67) |   |  
| 2 to 6 Hours Change from Baseline | 2.7 (3.48) | 0.8 (3.05) | < 0.0001 | 2.9 (3.41) | 2.1 (4.26) | 0.0494 |  
| Week 12 / LOCF Change from Baseline | 2.2 (4.31) | 1.2 (3.81) | 0.0060 | 2.9 (4.53) | 1.9 (4.82) | 0.0431 |  

LOCF – Last observation carried forward for those not providing data at 12 weeks of treatment.
**Figure 4**  Mean Change from Baseline in Qmax (mL/sec) by Treatment Group and Visit in Study 1

B – Baseline determination taken Day 1 of the study before the initial dose. Subsequent values are observed cases except for LOCF values.

LOCF – Last observation carried forward for those not providing data at 12 weeks of treatment.

Note – The first Qmax assessments at Day 1 were taken 2-6 hours after patients received the first dose of double-blind medication.

Note – Measurements at each visit were scheduled 2-6 hours after dosing (approximate peak plasma silodosin concentration).
B – Baseline determination taken Day 1 of the study before the initial dose. Subsequent values are observed cases except for LOCF values.

LOCF – Last observation carried forward for those not providing data at 12 weeks of treatment.

Note – The first Qmax assessments at Day 1 were taken 2-6 hours after patients received the first dose of double-blind medication.

Note – Measurements at each visit were scheduled 2-6 hours after dosing (approximate peak plasma silodosin concentration).

RAPAFLO had positive effects on quality of life based on the IPSS Quality of Life subscale, as measured at various intervals during dosing. The RAPAFLO treatment effects exceeded treatment effects of placebo. The percentage of RAPAFLO patients reporting to be in the delighted, pleased, mostly satisfied, and mixed categories increased from 6.9% to 32%, whereas the percentage of placebo patients using these descriptors increased from 7.2% to 22.5%.

Table 11  Summary of Quality of Life Related to Urinary Symptoms in Two Randomized, Controlled, Double-Blind Studies

<table>
<thead>
<tr>
<th>IPSS Question 8 Responses</th>
<th>Treatment, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Silodosin (n = 466)</td>
</tr>
<tr>
<td>Baseline</td>
<td></td>
</tr>
<tr>
<td>Delighted, pleased, or mostly satisfied</td>
<td>32 (6.9)</td>
</tr>
<tr>
<td>Mixed about equally satisfied and dissatisfied</td>
<td>126 (27.0)</td>
</tr>
<tr>
<td>Mostly dissatisfied, unhappy, or terrible</td>
<td>308 (66.1)</td>
</tr>
<tr>
<td>Week 12 (LOCF)</td>
<td></td>
</tr>
<tr>
<td>Delighted, pleased, or mostly satisfied</td>
<td>149 (32.0)</td>
</tr>
<tr>
<td>Mixed about equally satisfied and dissatisfied</td>
<td>141 (30.3)</td>
</tr>
<tr>
<td>Mostly dissatisfied, unhappy, or terrible</td>
<td>176 (37.3)</td>
</tr>
</tbody>
</table>

LOCF – Last observation carried forward for those not providing data at 12 weeks of treatment.
Long Term Treatment of BPH

Patients in Studies 1 and 2 who received either RAPAFLO or placebo were allowed to continue in a 40-week open-label extension study. Patients who received RAPAFLO in the double-blind period continued to see improvements in total IPSS as well as irritative and obstructive symptoms for up to 1 year of treatment; total IPSS score decreased by an additional 1.6 in these patients. Figure 6 provides results for all patients in the open-label extension study.

Figure 6  Mean Change (SD) from Baseline (End of Double-Blind Studies) to Week 40 in IPSS Total Score and Subscores in Open-Label Extension Study (Evaluable Population, N = 429)

![Graph showing mean change in IPSS total score and subscores](image)

DETAILED PHARMACOLOGY

Silodosin has high affinity for $\alpha_{1A}$-Adrenergic Receptor ($\alpha_{1A}$-AR) subtype (pKi value: 10.4). The selectivity of silodosin for $\alpha_{1A}$-AR subtype was 162 times and 55.0 times higher than for subtypes $\alpha_{1B}$-AR and $\alpha_{1D}$-AR, respectively. In addition, the selectivity of silodosin for subtype $\alpha_{1A}$-AR was the highest among other $\alpha_{1}$-AR blockers, including tamsulosin hydrochloride, prazosin hydrochloride, and terazosin hydrochloride. Silodosin had a strong inhibitory effect on contraction induced by treatment with noradrenalin in the lower urinary tract organs such as the prostate, the urethra and the trigone of the urinary bladder on which subtype $\alpha_{1A}$-ARs are predominantly located (the $\text{pA}_2$ or $\text{pKb}$ value: 9.60, 8.71 and 9.35, respectively). The $\text{pA}_2$ values of the inhibitory effect on contraction induced by treatment with noradrenalin in the isolated
spleen of rats on which $\alpha_{1B}$-AR subtype is predominantly located, and in isolated thoracic aortas in rats on which $\alpha_{1D}$-AR is predominantly located, were 7.15 and 7.88, respectively. The receptor binding study and the function study using isolated organs revealed that silodosin had higher selectivity for $\alpha_{1A}$-AR subtype of the lower urinary tract organs compared to the other $\alpha_1$-AR blockers.

In human plasma two major metabolites of silodosin (those greater than 10 percent of parent drug systemic exposure at steady state) were identified and designated KMD-3213G and KMD-3293. The glucuronide conjugate of silodosin, KMD-3213G, which is not detected in animal plasma, had 1/8 times the affinity of silodosin for human $\alpha_1$-AR. In animals, this human metabolite had 1/4.5 times the affinity for $\alpha_{1A}$-AR subtype in rats, about 1/2 the inhibitory effect on contraction induced by noradrenalin in the isolated prostate in rats, and not greater than 1/10 the transferability to the prostate of silodosin. KMD-3293, the other major metabolite of silodosin in humans, was detected in animal plasma and had 1/42 times the affinity of silodosin for subtype $\alpha_{1A}$-AR in humans.

A rat model of benign prostatic hyperplasia, prepared by administering sex hormones, had overactive bladder-like contractions when urine accumulated in the body. Silodosin significantly inhibited the number of overactive cytid contractions. In secondary pharmacodynamic studies, silodosin had comparatively high binding affinities for $\beta_2$-AR as well as $\alpha_1$-ARs, but inhibited $\beta_2$-AR in the isolated uterus in pregnant rats at a higher concentration than the concentration at which silodosin inhibited $\alpha_1$-ARs in the prostate. Furthermore, silodosin had low affinities for other types of receptors except for $\beta_2$-AR, and accordingly was less likely to exhibit any effects through receptor types other than $\alpha_1$-ARs in clinical use.

The safety pharmacology studies of silodosin revealed minimally significant effects on the central nervous system or on the respiratory system. With regard to the cardiovascular system, a decrease in blood pressure of about 20% of the baseline values was seen in conscious dogs after oral administration of silodosin at 20 mg/kg, but silodosin had no effect on heart rate and electrocardiography in conscious dogs. Silodosin also inhibited hERG current at high concentrations and prolonged APD$_{90}$ in the myocardial action potential in isolated papillary muscle from guinea pigs. However, these effective concentrations (4,415 ng/mL) are about 72-fold higher than 61.6 ng/mL, the maximum concentration of silodosin in healthy adult human males receiving repeat oral administration of 8 mg, which is the recommended clinical dose. Thus, silodosin is expected to have little effect on the repolarization in the heart. In a thorough QT electrocardiography study, silodosin capsules 8 mg daily, silodosin capsules 24 mg daily, placebo daily, or a single dose of moxifloxacin 400 mg were administered to healthy male humans. Silodosin capsules 8 mg and 24 mg daily had no statistically significant effect on ECG intervals or cardiac repolarization relative to placebo. Furthermore, there was no dose-response relationship observed with the product.

The main plasma metabolite of silodosin is a glucuronide conjugate (KMD-3213G) that is formed via direct conjugation of silodosin by UDP-glucuronosyltransferase 2B7 (UGT2B7). The second major plasma metabolite (KMD-3293) is formed via alcohol and aldehyde dehydrogenases and reaches plasma exposures similar to that of silodosin. KMD-3213G, which is not detected in animal plasma, had 1/8 times the affinity of silodosin for human $\alpha_1$-AR. In animals, this human metabolite had 1/4.5 times the affinity for $\alpha_{1A}$-AR subtype in rats, about 1/2
the inhibitory effect on contraction induced by noradrenalin in the isolated prostate in rats, and not greater than 1/10 the transferability of silodosin to the prostate. The safety pharmacology studies in which KMD-3213G was intravenously injected revealed that KMD-3213G had no meaningful effects on the central nervous system, the respiratory system, or the cardiovascular system.

Metabolite KMD-3293 was detected in animal plasma and had 1/42 times the affinity of silodosin for subtype $\alpha_{1A}$-AR in humans.

**TOXICOLOGY**

**Acute Toxicity**

A single oral administration study in rats revealed that the approximate lethal dose was 800 mg/kg for males and females. The approximate lethal doses for male and female rats receiving an intravenous administration were 75 mg/kg and 90 mg/kg, respectively. The single administration study in dogs disclosed that the approximate lethal dose was 1500 mg/kg for orally administered silodosin and 50 mg/kg or more via intravenous injection.

| Table 12 Single Dose Toxicity Studies in Rats and Dogs after Oral and Intravenous Administration |
|------|-------|-----------------|
| **Species** | **Route** | **Doses (mg/kg)** |
| Rats | oral | 500, 1000, 2000 |
| | oral | 400, 800, 1600 |
| | I.V. | 0, 60, 75, 90 |
| Dogs | oral | 1500, 2000 |
| | oral | 1000, 1500 |
| | I.V. | 25, 50 |

**Chronic Toxicity**

A 1-month administration study in rats revealed fatty degeneration in liver hepatocytes given 60 mg/kg/day or more, and the no observed adverse effect level (NOAEL) of silodosin was estimated at 20 mg/kg/day. A 3-month repeat oral administration study in rats revealed moderate to severe fatty degeneration of hepatocytes and hypertrophy and eosinophilic changes of centrilobular hepatocytes in the males receiving 100 mg/kg/day or more, and hypertrophy of centrilobular hepatocytes in females receiving 400 mg/kg/day or more. The NOAEL of silodosin was estimated to be 25 mg/kg/day in males and 100 mg/kg/day in females. A 26-week oral
administration study in rats showed fatty degeneration of hepatocytes in males receiving 15 mg/kg/day or more and in females given 300 mg/kg/day. Males receiving 5 mg/kg/day showed only a mild fatty degeneration of hepatocytes, which was also seen in the control group. The NOAEL of silodosin was estimated to be 5 mg/kg/day. In a 2-week intravenous injection study in rats, mortality was noted in the 50 mg/kg/day group, and the NOAEL of silodosin was estimated to be 10 mg/kg/day.

Following a 28-day administration in rats, plasma evaluations revealed decreased thyroxine (T4) levels at all dosage levels (50-300 mg/kg/day), increased thyroid stimulating hormone (TSH) at 150 and 300 mg/kg/day, and decreased triiodothyronine (T3) at 300 mg/kg/day. Liver to body weight ratio was increased at 150 and 300 mg/kg/day, along with thyroid/parathyroid to body weight ratio in the 300 mg/kg/day group. Histopathological examination revealed centrilobular hepatocellular hypertrophy and hypertrophy of the thyroid follicular epithelium at 150 and 300 mg/kg/day. Increased hepatic microsomal T4-UDP-GT activity was observed in the 300 mg/kg/day group. Changes in the CYP-dependent enzyme activities also occurred. Most notable were the significant increases in CYP1A at all dosage levels, increases in CYP3A in the 150 and 300 mg/kg/day groups, increases in CYP2B in the 300 mg/kg/day group, and increases in lauric acid 11-hydroxylase and lauric acid 12-hydroxylase in the 150 and 300 mg/kg/day groups.

A 1-month oral administration study in dogs showed degeneration of the seminiferous tubular epithelium in animals receiving 25 mg/kg/day or more, with the NOAEL of silodosin estimated to be less than 25 mg/kg/day. A 13-week oral administration study in dogs revealed decreased body weights in both males and females in the 50 mg/kg/day group, and atrophy of the thymus and retarded maturation of the genitalia in males given 50 mg/kg/day. The NOAEL of silodosin was estimated to be 10 mg/kg/day. A 52-week oral administration study showed decreases in body weight, erythrocyte count, hemoglobin level, and hematocrit level in dogs given 80 mg/kg/day. The NOAEL of silodosin was estimated to be 20 mg/kg/day. A 2-week intravenous administration study revealed no marked changes, and the NOAEL of silodosin was estimated at 25 mg/kg/day.

**Table 13 Chronic Dose Toxicity Studies in Rats and Dogs after Oral and Intravenous Administration**

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>Duration of Dosing</th>
<th>Doses (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>oral</td>
<td>28 days</td>
<td>0, 50, 150, 300</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 month</td>
<td>0, 30, 100, 300, 800</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 month</td>
<td>0, 20, 60, 200, 600</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3 months</td>
<td>0, 25, 100, 400</td>
</tr>
<tr>
<td></td>
<td></td>
<td>26 weeks</td>
<td>0, 15, 60, 300</td>
</tr>
<tr>
<td></td>
<td></td>
<td>26 weeks</td>
<td>0, 1, 5</td>
</tr>
<tr>
<td></td>
<td>I.V.</td>
<td>2 weeks</td>
<td>0, 2, 10, 50</td>
</tr>
<tr>
<td>Dog</td>
<td>oral</td>
<td>2 weeks</td>
<td>50, 200, 500</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 month</td>
<td>0, 25, 100, 400</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13 weeks</td>
<td>0, 10, 50, 100/200</td>
</tr>
<tr>
<td></td>
<td></td>
<td>52 weeks</td>
<td>0, 5, 20, 80</td>
</tr>
<tr>
<td></td>
<td>I.V.</td>
<td>2 weeks</td>
<td>0, 1, 5, 25</td>
</tr>
</tbody>
</table>
**Mutagenicity Studies**

The reverse mutation assay in bacteria, the mouse lymphoma assay, the micronucleus test in mice, and the unscheduled DNA synthesis (UDS) test with rat hepatocytes revealed no genotoxicity potential for silodosin. A positive response was noted in the *in vitro* chromosomal aberration assay with Chinese hamster culture cells. This positive response was noted only at high levels in which cytotoxicity was noted. Silodosin did not induce chromosome aberrations in the *in vivo* genotoxicity study conducted when animals were exposed to the drug. Silodosin and its metabolites are not considered genotoxic.

**Carcinogenicity Studies**

In a 2-year carcinogenicity study, male mice were administered silodosin at 20, 60, and 100/200 mg/kg/day and female mice were administered 60, 150, and 400 mg/kg/day. Decreased body weights were observed at 200 mg/kg/day in males; therefore, the highest dosage was decreased to 100 mg/kg/day at Week 27 of administration. Mammary tumors and pituitary adenomas were observed in females treated at 150 mg/kg/day or higher and females treated at 400 mg/kg/day, respectively. The finding of pituitary adenomas was not statistically significant relative to controls in this study.

In a separate study conducted to elucidate the mechanism of onset of these increases in tumors, mice were administered oral doses of silodosin. Results confirmed increases in blood prolactin levels in the females receiving a single administration of 60 mg/kg/day or more and in females receiving repeat administration of 200 mg/kg/day or more. The mechanism of induction of pituitary and mammary tumors in rodents has been documented in publications as being due to the long-term, excessive stimulation by increased prolactin production and secretion from the pituitary, resulting from suppression of dopamine in the hypothalamus. Accordingly, increased mammary gland and pituitary tumors were considered to be induced by the same mechanism as described above. Non-neoplastic lesions such as an increase in hyperplasia of mammary glands in mice receiving 150 mg/kg/day or more, hyperplasia and hypertrophy of the anterior pituitary, and increases in acinus of the breast and enlarged mammary ducts in mice given 400 mg/kg/day may also be induced by increased production of prolactin and excessive stimulation to the mammary glands. Since prolactin, as well as estrogen and progesterone, accelerates adenomyosis of the uterus in mice, the increase in adenomyosis of the uterus in the female mice receiving 60 mg/kg/day or more may also be induced by increased blood prolactin levels. In addition, since prolactin stimulates corpus luteal function and increases the synthesis of progesterone as described above, increases in cystic uterine glands in the uterus of mice receiving 150 mg/kg/day or more and enlargement of uterine glands in mice given 400 mg/kg/day, may result from the increased secretion of the uterine gland caused by increased progesterone. It is believed that epidemiologic examination in humans revealed that a risk of mammary gland tumors increases with increased blood prolactin in women.

Increases in mammary gland and pituitary tumors in mice are not considered to be significant for the safety of silodosin in humans for the following reasons: repeated doses in mice of 60 mg/kg did not produce an increase in mammary tumors, and doses of 20 mg/kg did not produce an increase in prolactin levels in the blood. The 150 mg/kg/day dose is 125-fold greater, or more, on a mg/kg/day basis, than the recommended human clinical dose. Increases in prolactin levels
have also been reported to be increased by AR blockers for dopamine and include the AR blockers tamsulosin and prazosin. Therefore, these data indicate that silodosin caused a significant increase in mammary tumors at 150 and 400 mg/kg via an indirect or secondary mechanism involving increases in prolactin levels that also produced non-significant increases in pituitary and hepatocellular adenomas. Tamsulosin, likewise, has induced significant increases in mammary tumors via a secondary mechanism involving hyperprolactinemia.\(^5\) The mammary tumors noted are likely a class effect, for which there is no evidence of clinical relevance.

In the rat carcinogenicity study in which males were administered silodosin at 15, 50, and 150 mg/kg/day, and female rats received 15, 80, and 250 mg/kg/day; follicular cell adenomas of the thyroid were seen only in males of the 150 mg/kg/day group.

A repeat oral administration study in rats conducted to elucidate the possible mechanism of onset of increases in thyroid tumors revealed an increase in the liver UDP-GT activity in males receiving 150 mg/kg/day or more. A similar increase was noted in phenobarbital treated male rats. UDP-GT is involved in the metabolism and excretion of thyroid hormones. An increased UDP-GT activity enhances the catabolism of the thyroid hormones T3 and T4. The catabolism accelerates the secretion of TSH from the pituitary through an inhibition of the negative feedback mechanism. It is also known that since thyroid hormone binding protein is decreased due to catabolism, increases in unbound and free thyroid hormone occur in rats. Thus, the half-life of thyroid hormones is much shorter in rats compared to that of other species including humans.\(^6,7\) Accordingly, the increased catabolism of thyroid hormones quickly decreases thyroid hormone levels in the blood, and the secretion of TSH is consequently increased. Thyroid tumor induction by this indirect mechanism occurs in rats more frequently than in mice, and in males more frequently than in females.\(^6,7\) In contrast, it has been reported that thyroid tumors are not induced by this mechanism in humans.\(^6,7\) Therefore, the neoplastic changes in the thyroid observed in the rat carcinogenicity study are considered secondary to a rat-specific, indirect mechanism, and therefore do not pose a risk to humans for the following reasons: the neoplastic changes in the thyroid are induced by the change in the catabolism of thyroid hormones by the indirect mechanism of thyroid tumor induction as previously described,\(^6\) and there is a sufficient safety margin (72-fold) in dosage between the recommended clinical dose and 50 mg/kg/day in which follicular cell adenomas in the thyroid were not induced in male rats. Other drugs and chemicals have induced thyroid tumors in rats by a similar mechanism\(^9,10\) and have been approved for use.

**Reproduction and Teratogenicity Studies**

In a study of fertility and early embryonic development and implantation in rats, it was determined that the fertility index decreased due to changes in males, and the mating index decreased due to changes in females. The NOAEL was 6 mg/kg/day for the general toxicity in males and females and 6 mg/kg/day and 20 mg/kg/day for the reproductive function and early embryonic development in males and females, respectively. No teratogenic effects were noted in either rats or rabbits in the study. The NOAEL of silodosin for reproductive function and embryo-fetal development was 1000 mg/kg/day in rats and 60 mg/kg/day in rabbits. In a study for effects on pre- and post-natal development, including maternal function in rats, the NOAEL of silodosin was 30 mg/kg/day for maternal function and 300 mg/kg/day for offspring (F\(_1\)).
**Other Toxicology Studies**

In a local irritation study conducted using silodosin injections (0.2 mg/mL, pH 7.15) which were to be used in the clinical pharmacology study (BA / effect of diets), no significant muscle damage in rabbits and no human blood hemolysis were observed.

An antigenicity study confirmed that silodosin demonstrated no antigenic potential in mice or guinea pigs.

An *in vitro* phototoxicity study showed that silodosin produced mild phototoxicity when exposed to Balb/c 3T3 fibroblast cells *in vitro*. Treatment with silodosin resulted in a decrease in cell survival in the presence of UV-A light, which was illustrated by a decreased uptake of neutral red. An *in vivo* phototoxicity study exposing Crl:SKH1-hr hairless mice to UVR radiation from a xenon lamp after a single dose of silodosin was conducted. At the highest dosages of 500 mg/kg in male mice and 400 mg/kg in female mice, the mice exhibited mild, transient erythema indicative of phototoxicity. At lower dosages of 0 (Vehicle), 20, and 100 mg/kg in male mice and 0 (Vehicle), 60, and 150 mg/kg in female mice, no skin events indicative of phototoxicity were noted. The NOAEL in male mice was 100 mg/kg and the NOAEL in female mice was 150 mg/kg, which are much greater than the human clinical dose of 0.11 mg/kg.
REFERENCES


PART III: CONSUMER INFORMATION

PR RAPAFLO®
Silodosin Capsules

This leaflet is part III of a three-part "Product Monograph" published when RAPAFLO was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about RAPAFLO. Contact your doctor or pharmacist if you have any questions about the drug.

Please read this leaflet before you start taking RAPAFLO (silodosin). Also, read it each time you renew your prescription, just in case new information has been added.

ABOUT THIS MEDICATION

What the medication is used for:
Your doctor has prescribed RAPAFLO because you have a medical condition called benign prostatic hyperplasia (BPH). This only occurs in men.

What it does:
RAPAFLO relaxes muscles in the prostate, bladder neck and base. This results in improved urine flow, and reduced BPH symptoms.

When it should not be used:
Do not use RAPAFLO if you:
- are allergic to silodosin or to any ingredient in RAPAFLO (see What the nonmedicinal ingredients are);
- take other alpha1-blockers for high blood pressure;
- take antifungal or HIV drugs such as ketoconazole, itraconazole (Sporanox®), ritonavir (Kaletra®, Norvir®);
- have severe liver problem; or
- have severe kidney problem.

What the medicinal ingredient is:
Silodosin

What the nonmedicinal ingredients are:
D-mannitol, magnesium stearate, pregelatinized starch, and sodium lauryl sulfate. The size #1 and #3 hard gelatin capsules contain gelatin and titanium dioxide. The #1 capsules are printed with edible ink containing FD&C Blue No. 1 Aluminum Lake and yellow iron oxide. The #3 capsules are printed with edible ink containing yellow iron oxide.

What dosage forms it comes in:
Hard gelatin capsules.
8 mg capsules contain 8 mg of silodosin.
4 mg capsules contain 4 mg of silodosin.

WARNINGS AND PRECAUTIONS

RAPAFLO may lower blood pressure (postural hypotension), and may make you feel dizzy, especially when getting up from a lying or sitting position particularly if you are taking medications to lower blood pressure or have low blood pressure. In such cases, lie down until the symptoms have completely disappeared. Do not drive or operate machinery until you know how RAPAFLO affects you.

RAPAFLO is not indicated nor recommended for use in women and children.

Prostate cancer and BPH cause many of the same symptoms. Prior to starting RAPAFLO, your doctor will examine you to rule out the presence of prostate cancer.

Tell your doctor or pharmacist, before using the medication, if:
- you suffer liver or kidneys problems;
- you have ever had a reaction to the ingredients of this medication; or
- you have had low blood pressure or signs of low blood pressure [fainting, dizziness] after taking another medicine.

If you will have eye surgery, you must inform your eye surgeon that you are currently using RAPAFLO. Intraoperative Floppy Iris Syndrome (IFIS) has been reported during cataract surgery in some patients who take or have taken alpha1-blockers.

INTERACTIONS WITH THIS MEDICATION

RAPAFLO is broken down by specific enzymes in the liver. It is not known how combined use of drugs, or herbal products that are also broken down by the same enzymes, or grapefruit juice may influence the effectiveness or unwanted side effects of these drugs or herbal medicines.

Before using any prescription, over-the-counter medicines or herbal products, check with your doctor or your pharmacist.

Drugs that interact with RAPAFLO include:
- Alpha1-blockers for high blood pressure or prostate problems
- Certain anti-infection drugs such as ketoconazole, clarithromycin, itraconazole (Sporanox®) and ritonavir (Kaletra®, Norvir®)
PROPER USE OF THIS MEDICATION

Usual dose:
Follow your doctor’s instructions very carefully about how to take RAPAFLO.

The recommended dosage is one capsule (8 mg) daily to be taken right after a meal, at the same time each day.

For those with moderate renal impairment, the recommended dosage is one capsule (4 mg) daily to be taken right after meal, at the same time each day.

If you stop taking RAPAFLO for several days, you must check with your doctor before starting it again.

Overdose:
Overdose of silodosin may lead to low blood pressure and change in heart rate.

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all prescription drugs, RAPAFLO may cause side effects. The most common side effect seen with RAPAFLO is an orgasm with reduced or no semen. This side effect is reversible with discontinuation of the product. Other common side effects include dizziness, diarrhea, lightheadedness upon standing or sitting up abruptly, headache, swelling of the throat and nasal passages, and stuffy nose. Cases of itching, hives, shortness of breath, eosinophilic pneumonia (cough, fever, difficulty breathing), dry cough, swelling under the skin, peeling of skin, redness of skin, and swelling of the face have also been reported. If these side effects persist or become bothersome, please check with your physician or pharmacist.

As with other alpha-blockers, RAPAFLO can cause a drop in blood pressure upon changing from a sitting to a standing position, especially when you start treatment. This may lead to fainting, dizziness, or lightheadedness, upon standing or sitting up abruptly. Be careful when driving, operating machinery, or when doing any dangerous activities until you know how RAPAFLO affects you. This is important if you already have a problem with low blood pressure or take medicines to treat high blood pressure. If you begin to feel dizzy or lightheaded, lie down with your legs and feet up. If your symptoms do not improve call your doctor.

If you are undergoing cataract surgery or surgery because of cloudiness in your lens you should inform your ophthalmologist that you are taking RAPAFLO.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td>Dizziness</td>
<td>✅</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>✅</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Fainting</td>
<td>✅</td>
</tr>
<tr>
<td></td>
<td>Lightheadedness upon standing or sitting up abruptly</td>
<td>✅</td>
</tr>
<tr>
<td></td>
<td>Liver disease or liver problems</td>
<td>✅</td>
</tr>
<tr>
<td></td>
<td>Allergic reactions (swollen tongue, swollen throat)</td>
<td>✅</td>
</tr>
<tr>
<td></td>
<td>Skin rash</td>
<td>✅</td>
</tr>
<tr>
<td></td>
<td>Red or purple discoloration of the skin caused by bleeding underneath the skin (known as purpura)</td>
<td>✅</td>
</tr>
<tr>
<td>Rare</td>
<td>Feeling of rapid beating of the heart that may be more forceful (palpitation)</td>
<td>✅</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking RAPAFLO, contact your doctor or pharmacist.
HOW TO STORE IT

RAPAFLO capsules should be stored at controlled room temperature (15°C to 30°C). Protect from light and moisture.

Keep RAPAFLO out of reach of children.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
           Health Canada
           Postal Locator 0701E
           Ottawa, Ontario
           K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals, can be found at www.actavis.ca or by contacting Actavis Specialty Pharmaceuticals Co., at 1-855-892-8766.

This leaflet was prepared by:
Actavis Specialty Pharmaceuticals Co.
Mississauga, Ontario L5N 6J5
CANADA

Under Licence From:
Kissei Pharmaceutical Co., Ltd.
Nagano
JAPAN

RAPAFLO is a registered trademark of Actavis, Inc. used under licence by Actavis Specialty Pharmaceuticals Co.

Date of Preparation: January 14, 2015